FPT-SOFTWARE/SCSK-EU
19.4.2022 05:02:12 CEST | Business Wire | Press release
Vietnam’s leading Digital Transformation services provider FPT Software has recently unveiled its partnership with SCSK Europe, a subsidiary of the Japan-based system integrator SCSK Corporation. The collaboration affirms FPT Software’s robotic process automation (RPA) expertise and further expands its foothold in the European market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220418005262/en/
Applying “Fast Automation” framework, FPT Software has successfully helped SCSK Europe streamline six internal processes by deploying its award-winning RPA platform akaBot in four weeks. The offshore team then provided a comprehensive understanding of RPA’s benefits and armed SCSK employees with the necessary skills and mentality for the upcoming changes with the emergence of digital transformation. Following their internal success, SCSK Europe introduced FPT Software’s akaBot to their clients in the Chemical and Agriculture industries to help replace 100 percent human effort in their data extraction and loan credits approval processes.
"RPA is a powerful tool to resolve the bottleneck in business processes, delivering a much streamlined and efficient workflow. We believe that we can always extend the automation horizons even more by integrating RPA robots with other intelligent technologies,” said Masatoshi Chiba – General Manager, SCSK EU.
“With that expectation in mind, we decided to partner with akaBot, one of the leading vendors in developing hyper-automation solutions from FPT. Since 2018, we have established MOU for the comprehensive partnership to seek to supply a wider range of services and solutions and to expand our operations in the global through this partnership with FPT," Masatoshi Chiba further shared.
According to FPT Software Chief Operating Officer Tran Dang Hoa, the collaboration "paved the way for FPT Software’s expansion in robotic automation and digital transformation in the EU and on a global scale."
"Like SCSK, more and more firms worldwide are adopting RPA and hyper-automation to enhance operations," Tran Dang Hoa said. "As a global top 30 RPA solution provider, we aspire to accompany businesses to overcome pressing challenges, boost their productivity and save costs," he added.
FPT Software and SCSK’s partnership dates back to 2018 when the two cooperated in supporting the overseas expansion of Japanese companies, especially in financial and automotive systems development. Both sides joined forces in providing IT Services and business development through the Asia Pacific operations of major SCSK’s shareholder – Sumitomo Corporation.
First entering the European market in 2008, FPT Software has established seven offices and development centers, and is determined to penetrate further with digital transformation as the key driving force. The global IT firm targeted this strategic area as its first port for capital commitment in the value of 100 million dollars in the upcoming years, with the UK and Germany as two major geographies.
About FPT Software
FPT Software is a global technology and IT services provider headquartered in Vietnam, with USD 632.5 million in revenue and 22,500 employees in 26 countries. As a pioneer in digital transformation, the company delivers world-class services in Smart factories, Digital platforms, RPA, AI, IoT, Cloud, AR/VR, BPO, and more. It has served 700+ customers worldwide, a hundred of which are Fortune Global 500 companies in the industries of Automotive, Banking and Finance, Logistics & Transportation, Utilities, and more. For further information, please visit http://www.fpt-software.com .
About SCSK EU
SCSK Europe Ltd. was established in London in 1990 as a fully-owned subsidiary of SCSK Corporation, one of Japan's leading IT service companies with more than 14,000 employees. We are One Stop IT Service Provider and a proven strategic business partner to Japanese-related corporations operating in EMEA/CIS providing various IT Solutions including RPA. For further information, please visit SCSK Europe Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005262/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom